ACP
ABBV icon

Arcus Capital Partners’s AbbVie ABBV Stock Holding History

Arcus Capital Partners’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,438
Closed -$329K – 122
2025
Q4 		$329K Buy
+1,438
New +$328K 0.12% 106
2025
Q1 		– Sell
-4,404
Closed -$802K – 119
2024
Q4 		$802K Buy
+4,404
New +$810K 0.25% 48
2024
Q2 		– Sell
-4,404
Closed -$802K – 112
2024
Q1 		$802K Buy
4,404
+808
+22% +$139K 0.25% 48
2023
Q4 		$557K Buy
+3,596
New +$524K 0.2% 61

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Arcus Capital Partners's ABBV Position: Q1 2026 in Review

Arcus Capital Partners sold out of AbbVie (ABBV) in Q1 2026, closing a stake of 1,438 shares — an estimated $329K sold.

Arcus Capital Partners first reported a position in ABBV in Q4 2023 and held it in 4 quarters. The position peaked at $802K in Q4 2024. 4,097 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Arcus Capital Partners reported no remaining AbbVie position as of Q1 2026 after selling out during the quarter.
  • Arcus Capital Partners sold 1,438 AbbVie shares in Q1 2026, an estimated $329K.
  • Arcus Capital Partners first reported a position in AbbVie in Q4 2023 and held it in 4 quarters.
  • Arcus Capital Partners's AbbVie position peaked at $802K in Q4 2024.
  • 4,097 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Arcus Capital Partners's 13F filing for Q1 2026, filed 6 May 2026.